BiotechTube

SHR3680 + digoxin + Rosuvastatin calcium + metformin hydrochloride

Phase 1UNKNOWN
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Drug-drug Interaction,SHR3680

Conditions

Drug-drug Interaction,SHR3680

Trial Timeline

Nov 19, 2020 → Jul 5, 2021

NCT ID
NCT04621669

About SHR3680 + digoxin + Rosuvastatin calcium + metformin hydrochloride

SHR3680 + digoxin + Rosuvastatin calcium + metformin hydrochloride is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Drug-drug Interaction,SHR3680. The current trial status is unknown. This product is registered under clinical trial identifier NCT04621669. Target conditions include Drug-drug Interaction,SHR3680.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04621669Phase 1UNKNOWN

Competing Products

15 competing products in Drug-drug Interaction,SHR3680

See all competitors
ProductCompanyStageHype Score
EC905 + verapamilAstellas PharmaPhase 1
33
rosuvastatin + fidaxomicinAstellas PharmaPhase 1
33
enzalutamide + rifampinAstellas PharmaPhase 1
33
ASP3652 + Gemfibrozil + RepaglinideAstellas PharmaPhase 1
33
napabucasin + cytochrome P450 (CYP450) probe drugs or BCRP transporter substrateSumitomo PharmaPhase 1
33
Pyrotinib Maleate + EfavirenzJiangsu Hengrui MedicinePhase 1
33
Rifampin + SHR1459Jiangsu Hengrui MedicinePhase 1
33
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
33
BMS-986020 + Montelukast + Flurbiprofen + DigoxinBristol Myers SquibbPhase 1
32
Simvastatin + VoclosporinAurinia PharmaceuticalsPhase 1
28
Omeprazole 40 MG + Famotidine 40 mg + Telotristat ethyl 250 mgLexicon PharmaceuticalsPhase 1
28
pitavastatin + pitavastatin single dose combined with ceftobiproleBasilea PharmaceuticaPhase 1
28
elafibranor + CHRONO-INDOCIDGenfitPhase 1
25
Raxone (idebenone 150 mg) + Midazolam 2,5 mgSanthera PharmaceuticalsPhase 1
25
Midazolam 5mg Syrup + Vapendavir 264 mg BID + Vapendavir 528 mg QDVaxartPhase 1
25

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85